IPO Of Biologics Division Likely In Next Few Years, Says Biocon’s Kiran Mazumdar Shaw

Biocon shares have lost 14 percent since the company released its fourth-quarter earnings last month. Kiran Mazumdar Shaw, CMD of Biocon, spoke to CNBC-TV18 about the financial results and growth prospects.

“I don’t think you should be looking at quarterly growth as being a muted growth because remember we have just one biosimilar is the US market, we have just entered the European markets and we have delivered strong robust growth in emerging markets. So I think you should not be judging this kind of performance in the way the market is looking at the numbers so I find it not very reasonable in the way it is being looked at,” Shaw said on Wednesday.

Talking about the revenue guidance, Mazumdar said, “We do not give guidance but let me give you some optics. We are now in the US market with Fulphila or pegfilgrastim where we have already captured 20 percent market share, we have a trastuzumab launch coming up later and we expect to launch biosimilar Insulin Glargine sometime next year.”

“All these launches including the fact that we also have our biosimilars approved in Europe where we have entered the market with biosimilar trastuzumab, Glargine, Fulphila and adalimumab. Therefore, what you can expect in the year ahead is a strong robust growth,” she said.

On Mylan-Biocon front, Shaw said, “Mylan-Biocon have an early mover advantage and we have factored in the competitive landscape when we talk about robust growth.

With regards to the company’s plans for biosimilars, the CMD said, “We certainly have plans to take the company to an IPO in the next few years and we will do it at the right time when we can monetise maximum value.” – CNBC TV18